Pharsight

Acrotech Biopharma patents expiration

1. Beleodaq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6888027 ACROTECH BIOPHARMA Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH BIOPHARMA Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 03, 2021
New Chemical Entity Exclusivity(NCE) Jul 03, 2019
Orphan Drug Exclusivity(ODE-68) Jul 03, 2021

Drugs and Companies using BELINOSTAT ingredient

NCE-1 date: 03 July, 2018

Market Authorisation Date: 03 July, 2014

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage

BELEODAQ family patents

Family Patents

2. Evomela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 ACROTECH BIOPHARMA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9200088 ACROTECH BIOPHARMA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US11020363 ACROTECH BIOPHARMA Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(5 years from now)

US10864183 ACROTECH BIOPHARMA Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(5 years from now)

US10940128 ACROTECH BIOPHARMA Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
Jun, 2030

(6 years from now)

US9493582 ACROTECH BIOPHARMA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)

US10040872 ACROTECH BIOPHARMA Alkylated cyclodextrin compositions and processes for preparing and using the same
Jan, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 10, 2023
Orphan Drug Exclusivity(ODE-110) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage

EVOMELA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Folotyn patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6028071 ACROTECH BIOPHARMA Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Jul, 2022

(1 year, 10 months ago)

US7622470 ACROTECH BIOPHARMA Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(11 months from now)

US8299078 ACROTECH BIOPHARMA Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Sep 24, 2016
New Chemical Entity Exclusivity(NCE) Sep 24, 2014

Drugs and Companies using PRALATREXATE ingredient

NCE-1 date: 24 September, 2013

Market Authorisation Date: 24 September, 2009

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FOLOTYN before it's drug patent expiration?
More Information on Dosage

FOLOTYN family patents

Family Patents

4. Fusilev patents expiration

FUSILEV IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6500829 ACROTECH BIOPHARMA Substantially pure diastereoisomers of tetrahydrofolate derivatives
Mar, 2022

(2 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-10) Apr 29, 2018
Orphan Drug Exclusivity(ODE) Mar 07, 2015
New Indication(I-637) Apr 29, 2014

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Market Authorisation Date: 07 March, 2008

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS

How can I launch a generic of FUSILEV before it's drug patent expiration?
More Information on Dosage

FUSILEV family patents

Family Patents

5. Khapzory patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541012 ACROTECH BIOPHARMA Compositions comprising disodium levofolinate
Mar, 2039

(14 years from now)

Drugs and Companies using LEVOLEUCOVORIN ingredient

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

KHAPZORY family patents

Family Patents